Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Roivant Sciences (ROIV) over the last 5 years, with Q4 2025 value amounting to $691000.0.

  • Roivant Sciences' Depreciation & Amortization (CF) fell 9453.58% to $691000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 million, marking a year-over-year decrease of 8788.61%. This contributed to the annual value of $14.1 million for FY2025, which is 3614.54% down from last year.
  • Roivant Sciences' Depreciation & Amortization (CF) amounted to $691000.0 in Q4 2025, which was down 9453.58% from $921000.0 recorded in Q3 2025.
  • Roivant Sciences' 5-year Depreciation & Amortization (CF) high stood at $16.8 million for Q4 2023, and its period low was $691000.0 during Q4 2025.
  • Over the past 5 years, Roivant Sciences' median Depreciation & Amortization (CF) value was $4.9 million (recorded in 2024), while the average stood at $6.0 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first surged by 20534.78% in 2022, then tumbled by 9453.58% in 2025.
  • Over the past 5 years, Roivant Sciences' Depreciation & Amortization (CF) (Quarter) stood at $4.2 million in 2021, then skyrocketed by 205.35% to $12.9 million in 2022, then soared by 30.28% to $16.8 million in 2023, then decreased by 24.78% to $12.6 million in 2024, then crashed by 94.54% to $691000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $691000.0 for Q4 2025, versus $921000.0 for Q3 2025 and $1.1 million for Q2 2025.